BETA

Beta Drugs Limited

Listed company · ISIN INE351Y01019 · NSE EQ · FV ₹10
Last price
₹2,095
+1.46%today
What this company does

Beta Drugs Limited is a listed company. It booked ₹126 cr of revenue in its latest quarter (Q1 FY27) and kept 13.1% of sales as profit.

60out of 100
Equitytale Health Score
Mixed

Healthier than 60% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,327–2,858 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
40

At close. Not part of the score.

Profitability & returns81

How much profit it earns on the money it employs

Balance sheet49

How much it owes, and whether earnings cover the interest

Cash quality50

Whether reported profit actually arrives as cash

Valuation21

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Looks broadly healthy
Strengths
Makes a profit
Promoters hold 59%
No promoter shares pledged
Strong 27% return on equity
Watch-outs
None flagged from our data

What if I invest in BETA?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹2,095 +1.46%
latest close · 2026-09-17
1-year return
+498.6%
52-wk low ₹31952-wk high ₹2,808
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio35.4High
LowAverageHigh
P/B ratio9.49High
Below bookModerateHigh
EV / EBITDA20.3High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity26.9%Strong
WeakFairStrong ▸15%
Return on capital25.4%Strong
WeakFairStrong
Net margin13.1%Decent
ThinDecentStrong
EBITDA margin23.1%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.60Moderate
LowModerateHigh ▸1
Interest cover9.6×Strong
RiskyOkayStrong ▸5×
Current ratio3.10Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹2,322 cr
Book value
₹221
EPS
₹14.78
latest quarter
Net debt
₹23 cr
owes more than its cash
Enterprise value
₹2,345 cr
EBITDA
₹116 cr
annualised
EBIT
₹98 cr
annualised
Operating margin
19.6%
Return on assets
13.3%
Earnings yield
2.82%
P/S
4.62
Sales / share
₹453.0
Tax rate
25.2%
Face value
₹10
Shares
1.1 cr
Working capital
₹227 cr
Current assets
₹335 cr
Current liabilities
₹108 cr
Delivery %
52.1%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹267₹431, midpoint ₹349

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹126 cr
Other Income₹2 cr
Total Income₹127 cr
Cost of Materials₹50 cr
Purchases of Stock-in-Trade₹0 cr
Inventory Change (±)₹4 cr
Employee Benefit Expense₹20 cr
Finance Costs₹3 cr
Depreciation & Amortisation₹4 cr
Other Expenses₹23 cr
Total Expenses₹105 cr
Profit before Tax₹22 cr
Tax Expense₹6 cr
Net Profit₹16 cr
Net margin on total income13.0%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹55 cr42.9%
Employee benefit expense₹20 cr16.0%
Finance costs₹3 cr2.0%
Depreciation & amortisation₹4 cr3.4%
Other expenses₹23 cr18.3%
Tax expense₹6 cr4.4%
Profit for the period₹16 cr13.0%
Total income ₹127 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue87 cr94 cr126 cr
Total income90 cr97 cr127 cr
Expenses79 cr85 cr105 cr
Profit before tax10 cr12 cr22 cr
Tax2 cr3 cr6 cr
Net profit (owners' share)9 cr9 cr16 cr
Net margin (owners' share, on revenue)9.8%9.6%13.1%
EPS (₹)8.408.9314.78
Balance sheet & cash flow · as of Mar 2026
Moderate debt
Total assets
₹496 cr
Shareholder equity
₹245 cr
parent shareholders
Total debt
₹148 cr
Cash
₹125 cr
Who owns it · 2026-06-30
No pledge
Promoter
59.1%
FII / Foreign
1.0%
DII / Domestic
6.2%
Retail / others
33.6%
Promoter stake down 7.6% over the last 12 quarters.
Smart-money activity
Insider trades
SoldNeeraj Batra · Promoters1.85 L · ₹31.2 cr13 Nov 25
BoughtHeena Batra · Promoters2927 Mar 25
BoughtNeeraj Batra · Promoters3.17 L27 Mar 25
Bulk / block deals
SoldNEERAJ BATRA · NSE1.85 L @ ₹1,68613 Nov 25
BoughtAIRAVAT CAPITAL TRUST II · NSE1.56 L @ ₹1,68613 Nov 25
BoughtBATRA VIJAY KUMAR · NSE50,400 @ ₹84.951 Sep 20
Stake changes
SoldNeeraj Batra, Rahul Batra, Varun Batra, Heena Batra & Aditi Batra · promoter→ 64.90% · 1.85 L13 Nov 25
BoughtNeeraj Batra, Rahul Batra, Varun Batra, Heena Batra & Aditi Batra · promoter→ 66.73% · 3.21 L27 Mar 25
BoughtAshish R Kacholia→ 12.12% · 1.95 L30 Aug 21
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Special shareholder meeting · 4 Feb 2026
See the official result
1
Approval of increase in Authorised Share Capital of the Company and Consequent Alteration in The Capital Clause of The Memorandum of Association of the Company.
Backed by 100% of shareholders other than promotersneeded 50%
2.83 L votes for, 0 against · 0% of mutual funds and other big investors said no
2
Approval of Beta Drugs Limited Employee Stock Option Plan 2026
Backed by 100% of shareholders other than promotersneeded 75%
2.83 L votes for, 0 against · 0% of mutual funds and other big investors said no
3
Approval of Extending the Benefits of Beta Drugs Limited Employee Stock Option Plan 2026 to the Employees of the Group Companies including Holding, Subsidiary and Associate Companies of the Company.
Backed by 100% of shareholders other than promotersneeded 75%
2.83 L votes for, 0 against · 0% of mutual funds and other big investors said no
4
Approval of the Issue and Offer of 2,83,668 (Two Lakh Eighty-Three Thousand Six Hundred and Sixty-Eight) Equity Shares of the Company of Face Value of INR 10 Each, at a Price of INR 1712.49 (Indian Rupees One Thousand Seven Hundred Twelve and Forty-Nine Paisa) Per Equity Share Including a Premium of INR 1702.49 (Indian Rupees One Thousand Seven Hundred Two and Forty-Nine Paisa) Per Equity Share to the specified Persons.
Backed by 100% of shareholders other than promotersneeded 75%
2.83 L votes for, 0 against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 5 named members
owning 59.1% between them · as of 2026-06-30
Neeraj Batra58.40%
Rahul Batra0.38%
Varun Batra0.31%
Aditi Batra0.01%
Heena Batra0.01%

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹117 cr raised in Nov 2024 by selling shares to selected investors

As of Jun 2026, the company says it has spent 41% of what it set aside. Brickwork Ratings India Private Limited watches the spending on the exchange’s behalf.

Facility Upgradation of 100% Subsidiary - Adley Formualtions Pvt Ltd.
28%
of what was set aside
Facility Upgradation of 100% Subsidiary - Adley Lab Ltd.
27%
of what was set aside
R & D facilty (new setup)
6%
of what was set aside
Geographical Expansion it includes new registrations, audits, dossiers costs, bioequivalence studies cost.
0%
of what was set aside
Capital Expenditure (Manufacturing- new setup)
22%
of what was set aside
Capital Investment (including capital acquisitions)
100%
of what was set aside
Spent by quarter: 9%17%18%20% (to Mar 2026) · 1 earlier quarter is left out because the company restated its figures

The rupee amounts in this company’s own breakdown don’t add up to the amount it says it raised — a common filing slip, where a table meant to be read in lakhs is entered as whole rupees. Rather than guess which is right, we show only the percentages, which are unaffected.

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.